BRPI0406745A - Formulações parenterais de peptìdeos para o tratamento de lupus eritematoso sistêmico - Google Patents

Formulações parenterais de peptìdeos para o tratamento de lupus eritematoso sistêmico

Info

Publication number
BRPI0406745A
BRPI0406745A BR0406745-2A BRPI0406745A BRPI0406745A BR PI0406745 A BRPI0406745 A BR PI0406745A BR PI0406745 A BRPI0406745 A BR PI0406745A BR PI0406745 A BRPI0406745 A BR PI0406745A
Authority
BR
Brazil
Prior art keywords
peptide
amino acids
consecutive amino
sequence
systemic lupus
Prior art date
Application number
BR0406745-2A
Other languages
English (en)
Inventor
Sharon Cohen-Vered
Esmira Naftali
Vera Weinstein
Adrian Gilbert
Ety Klinger
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of BRPI0406745A publication Critical patent/BRPI0406745A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

"FORMULAçõES PARENTERAIS DE PEPTìDEOS PARA O TRATAMENTO DE LUPUS ERITEMATOSO SISTêMICO". A presente invenção provê uma composição farmacêutica compreendendo: um veículo aquoso; de 0,1 mg/ml a 20 mg/ml da composição de um sal farmaceuticamente aceitável de a) peptídeo compreendendo pelo menos 12 e no máximo 30 aminoácidos consecutivos possuindo uma seq³ência correspondendo a (i) uma seq³ência de aminoácidos encontradas dentro de uma região determinante de complementaridade (CDR) de uma cadeia leve ou pesada de um anticorpo 16/6 Id de anti-DNA monoclonal humano que induz uma resposta à doença tipo lupus eritematoso sistêmico (SLE) em camundongo, ou b) um peptídeo compreendendo aminoácidos consecutivos possuindo a seq³ência mostrada por qualquer das SEQ ID NOS. 8-17, ou c) um peptídeo compreendendo aminoácidos consecutivos possuindo uma seq³ência de qualquer de e b) , ou pelo menos duas das seq³ências em (a) (1), (a) (ii) e (b) (i) a (b) (x), ou d) um peptídeo compreendendo aminoácidos consecutivos possuindo uma seq³ência compreendendo pelo menos duas seq³ências idênticas incluídas em (a) (i) , (a) (ii) e (b) (i) a (b) (x) ; e um intensificador de solubilidade, em que tanto o peptídeo quanto o intensificador de solubilidade são dissolvidos no veículo aquoso; e em que a composição possui um pH entre 4 e 9, e um método de alívio de sintomas de SLE em humanos pela administração de uma quantidade eficaz da composição.
BR0406745-2A 2003-01-14 2004-01-14 Formulações parenterais de peptìdeos para o tratamento de lupus eritematoso sistêmico BRPI0406745A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43991803P 2003-01-14 2003-01-14
PCT/US2004/000948 WO2004064787A2 (en) 2003-01-14 2004-01-14 Parenteral formulations of peptides for the treatment of systemic lupus erythematosus

Publications (1)

Publication Number Publication Date
BRPI0406745A true BRPI0406745A (pt) 2005-12-20

Family

ID=32771757

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0406745-2A BRPI0406745A (pt) 2003-01-14 2004-01-14 Formulações parenterais de peptìdeos para o tratamento de lupus eritematoso sistêmico

Country Status (21)

Country Link
US (3) US20050008634A1 (pt)
EP (1) EP1594434B1 (pt)
JP (2) JP4817068B2 (pt)
KR (1) KR20050100617A (pt)
CN (1) CN1774259B (pt)
AU (1) AU2004206842A1 (pt)
BR (1) BRPI0406745A (pt)
CA (1) CA2513320C (pt)
CO (1) CO5640143A2 (pt)
CR (1) CR7938A (pt)
DK (1) DK1594434T3 (pt)
EA (1) EA009123B1 (pt)
EC (1) ECSP055961A (pt)
ES (1) ES2606464T3 (pt)
IL (1) IL169574A (pt)
IS (1) IS7972A (pt)
MX (1) MXPA05007549A (pt)
NO (1) NO20053773L (pt)
NZ (1) NZ541658A (pt)
WO (1) WO2004064787A2 (pt)
ZA (1) ZA200506206B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL141647A0 (en) * 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
KR20050100617A (ko) * 2003-01-14 2005-10-19 테바 파마슈티컬 인더스트리즈 리미티드 전신 홍반 루푸스 치료용 펩티드의 비 경구 제형
JP2006516034A (ja) * 2003-01-14 2006-06-15 テバ ファーマシューティカル インダストリーズ リミティド 全身性エリテマトーデスを治療するためのペプチドの非経口製剤
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
MX2011005051A (es) * 2008-11-17 2011-06-01 Genentech Inc Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas.
WO2013123254A1 (en) 2012-02-15 2013-08-22 Cydex Pharmaceuticals, Inc. Manufacturing process for cyclodextrin derivatives
BR112015000497A2 (pt) * 2012-07-12 2017-06-27 Sanofi Sa composição anti-tumoral compreendendo o composto 1-(6-{[6-(4-fluorofenil)[1,2,4]triazolo[4,3-b]piridazin-3-il]sulfanil}-1,3-benzotiazol-2-il)-3-(2-morfolin-4-iletil)ureia
KR102112119B1 (ko) 2012-10-22 2020-05-19 사이덱스 파마슈티칼스, 인크. 알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법
WO2014193611A1 (en) * 2013-05-29 2014-12-04 Oklahoma Medical Research Foundation Bright/arid3a function/expression as a marker for systemic lupus erythematosus severity and intensity
WO2015013669A1 (en) 2013-07-26 2015-01-29 The Regents Of The University Of California Mps peptides and use thereof
US10314889B2 (en) * 2013-12-20 2019-06-11 The Regents Of The University Of California Suppression of allergic lung inflammation and hyperreactivity
PT3183295T (pt) 2014-08-22 2023-11-03 Cydex Pharmaceuticals Inc Composições de ciclodextrina alquilada fracionada e processos para preparação e utilização das mesmas
CN115400220A (zh) 2015-12-30 2022-11-29 豪夫迈·罗氏有限公司 减少聚山梨酯降解的制剂
JOP20170017B1 (ar) * 2016-01-25 2021-08-17 Amgen Res Munich Gmbh تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
CA3047706A1 (en) 2017-01-05 2018-07-12 Yeda Research And Development Co. Ltd. Peptides for treating sjogren's syndrome
WO2018186343A1 (ja) * 2017-04-04 2018-10-11 日東電工株式会社 凍結乾燥体の製造方法及びその製造装置
US10975121B2 (en) 2017-06-24 2021-04-13 Cytogel Pharma, Llc Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof
WO2019108285A1 (en) * 2017-11-30 2019-06-06 Cytogel Pharma, Llc Novel analgesic pharmaceutical formulations and uses thereof
CN112143707A (zh) * 2020-09-29 2020-12-29 广东先康达生物科技有限公司 一种治疗自身免疫细胞的免疫细胞及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60184098A (ja) * 1984-03-02 1985-09-19 Suntory Ltd 新規なペプチド及びこれを有効成分とする利尿剤
US6407079B1 (en) * 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5126249A (en) * 1989-05-09 1992-06-30 Eli Lilly And Company Enzymatic removal of a protein amino-terminal sequence
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9200247D0 (en) * 1992-01-07 1992-02-26 Erba Carlo Spa Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
US6613536B1 (en) * 1995-03-28 2003-09-02 Yeda Research And Development Co. Ltd. Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
IL113159A0 (en) * 1995-03-28 1995-06-29 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
IL120503A0 (en) * 1997-03-20 1997-07-13 Hadasit Med Res Service Peptides for the treatment of systemic lupus erythematosis and pharmaceutical compositions containing them
US20020054872A1 (en) * 1997-03-20 2002-05-09 Yaakov Naparstek Peptides for the treatment of systemic lupus erythematosus and methods of treating systemic lupus erythematosus
SE9802938D0 (sv) * 1998-09-01 1998-09-01 Astra Ab Improved stability for injection solutions
IL141647A0 (en) * 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
JP2006516034A (ja) * 2003-01-14 2006-06-15 テバ ファーマシューティカル インダストリーズ リミティド 全身性エリテマトーデスを治療するためのペプチドの非経口製剤
KR20050100617A (ko) * 2003-01-14 2005-10-19 테바 파마슈티컬 인더스트리즈 리미티드 전신 홍반 루푸스 치료용 펩티드의 비 경구 제형
US7018891B2 (en) * 2003-12-16 2006-03-28 International Business Machines Corporation Ultra-thin Si channel CMOS with improved series resistance

Also Published As

Publication number Publication date
EP1594434B1 (en) 2016-09-07
IS7972A (is) 2006-07-15
DK1594434T3 (da) 2017-01-02
EA200501131A1 (ru) 2006-04-28
CA2513320A1 (en) 2004-08-05
ECSP055961A (es) 2006-04-19
US20050008634A1 (en) 2005-01-13
JP4817068B2 (ja) 2011-11-16
MXPA05007549A (es) 2006-05-19
CA2513320C (en) 2018-03-27
CR7938A (es) 2006-05-31
NZ541658A (en) 2008-04-30
EP1594434A4 (en) 2008-09-10
NO20053773D0 (no) 2005-08-08
NO20053773L (no) 2005-10-12
WO2004064787A3 (en) 2005-12-15
JP2006517540A (ja) 2006-07-27
KR20050100617A (ko) 2005-10-19
EA009123B1 (ru) 2007-10-26
US20130023485A1 (en) 2013-01-24
EP1594434A2 (en) 2005-11-16
ZA200506206B (en) 2006-12-27
ES2606464T3 (es) 2017-03-24
IL169574A0 (en) 2007-07-04
IL169574A (en) 2015-08-31
CN1774259B (zh) 2011-12-28
AU2004206842A1 (en) 2004-08-05
CO5640143A2 (es) 2006-05-31
CN1774259A (zh) 2006-05-17
US20090169559A1 (en) 2009-07-02
JP2011173888A (ja) 2011-09-08
WO2004064787A2 (en) 2004-08-05

Similar Documents

Publication Publication Date Title
BRPI0406745A (pt) Formulações parenterais de peptìdeos para o tratamento de lupus eritematoso sistêmico
CN101815724B (zh) 用于将轭合至其的试剂递送至组织的抑肽酶样多肽
CA2431600A1 (en) Molecules with extended half-lives, compositions and uses thereof
ATE454124T1 (de) Rekombinante anti-cd30-antikörper und deren verwendungen
JP2011511780A5 (pt)
AR058567A1 (es) Formulaciones de proteinas estables
WO2006056464A3 (en) Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
PE20060817A1 (es) Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina
HRP20230387T1 (hr) Farmaceutski pripravci koji sadrže anti-beta amiloidna antitijela
JP5990324B2 (ja) 生理活性ペプチド複合体
BR0306838A (pt) Peptìdeo não-nativo, ácido nucléico isolado, composição farmacêutica e kit para prevenção ou tratamento de uma doença modulada por crf2r
CO5640149A2 (es) Formulaciones parenterales de un peptido para el tratamiento de lupus sistematico eritematoso
FI3774879T3 (fi) C-terminaalisia vasta-ainemuunnoksia
ATE521702T1 (de) Krebsantigene und deren nutzung
DK0610446T3 (da) Syntetisk peptidspecificitet af antimyelin basic protein fra cerebrospinalvæske fra dissemineret sklerose
US8475800B2 (en) Phosphorylated derivatives of a U1-70K peptide and their use in the treatment of autoimmune pathologies
DE69615026D1 (de) Ein verbessertes peptid, immunogene zusammensetzung und impfstoff oder medizinische präparate, eine methode zur immunisierung von tieren gegen das hormon lhrh und analoge des lhrh-tendem-repeat-peptid und deren verwendung als impfstoff
BRPI0414139A (pt) métodos e composições para tratar infecções por herpes
BR0016129A (pt) Molécula de ácido nucléico, vetor recombinante, polipeptìdeo, racemase de aminoácido eucariótica, anticorpos, célula hospedeira, métodos para produzir polipeptìdeo, para detectar um parasita e uma proteìna eucariótica, para triar moléculas ativas, para detectar e quantificar a presença ou a ausência de uma sequência, para inibir uma proteìna eucariótica, para produzir uma racemase de aminoácido recombinante eucariótica e d-aminoácio e para prevenir ou inibir infecção, plasmìdeo, complexo imunológico, kit para detectar um parasita, fragmento de um polinucleotìdeo, proteìna eucariótica, processos para preparar uma proteìna eucariótica purificada, para detectar uma infecção e para infecção e para triar uma molécula, composição imunizadora, composição de vacina, qualquer modificação molecular do gene ou de um fragmento do gene, uso de qualquer modificação molecular ou bioquìmica da atividade enzimática da racemase, e, qualquer molécula ou composto
US20220185857A1 (en) Fms-like tyrosine kinase 3 ligand (flt3l)-based chimeric proteins
RU2007115411A (ru) Пептиды hsp60 и их apl-производные и фармацевтические композиции
DK0845034T3 (da) Peptid med pronociceptive egenskaber
AR014884A1 (es) Uso de un conjugado de angiotensina inmunogenico y composicion farmaceutica
WO2014160098A2 (en) Bordetella specific human recombinant antibodies and uses thereof
CN107106672B (zh) 用于预防和治疗免疫介导性疾病的针对胞壁酰肽的单克隆抗体

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.